Targeting the NLRP3 inflammasome for the treatment of inflammatory diseases
This seminar will be held using Zoom. Please register here:
The NLRP3 inflammasome has emerged as a key mediator of damaging inflammation in many chronic diseases which are a large, and increasing, burden on public health. Atherosclerosis, Alzheimer’s disease, Parkinson’s disease, asthma, liver disease, and arthritis are all associated with NLRP3 activation making it an attractive therapeutic target. I will describe our characterisation of MCC950, a potent and specific small molecule inhibitor of NLRP3, from its initial discovery to the determination of its mechanism of action. NLRP3 inhibitors are currently being evaluated in early clinical trials and I will discuss the potential therapeutic application of this new class of anti-inflammatory therapies.
Date: 12 October 2020, 12:00 (Monday, 1st week, Michaelmas 2020)
Venue: Kennedy Institute of Rheumatology, Headington OX3 7FY
Venue Details: This seminar will be held using Zoom. Please register here:
Speaker: Dr Rebecca Coll (Queen's University Belfast)
Organising department: Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS)
Organisers: Jennifer Pope (Kennedy Institute of Rheumatology), Professor Irina Udalova (Kennedy Institute of Rheumatology)
Organiser contact email address:
Host: Dr Jelena Bezbradica (The Kennedy Institute of Rheumatology)
Part of: Kennedy Institute Seminars
Booking required?: Required
Booking url:
Audience: Members of the University only
Editor: Jennifer Pope